1,2,3,4-tetrahydro-[2]naphthoyl chloride | 86346-43-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2,3,4-tetrahydro-[2]naphthoyl chloride
• 英文别名: (RS)-1,2,3,4-tetrahydro-naphthalene-2-carbonyl chloride；1,2,3,4-tetrahydronaphthalene-2-carboxylic acid chloride；1,2,3,4-tetrahydro-naphthalene-2-carbonyl chloride；1,2,3,4-Tetrahydronaphthalene-2-carbonyl chloride
• CAS: 86346-43-2
• 化学式: C₁₁H₁₁ClO
• 分子量: 194.661
• InChiKey: GBZFILBGEYHYAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,2,3,4-tetrahydro-[2]naphthoyl chloride 在 吡啶 、 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 12.25h， 生成 1,3-dimethyl-8-(1,2,3,4-tetrahydronaphthalen-2-yl)-7H-purine-2,6-dione
  参考文献：
  名称：

  Synthesis and in vitro bronchospasmolytic activity of 8-aryl, heteroaryl or arylalkyl theophyllines

  摘要：

  Twenty-four 8-aryl- or 8-heteroaryl-substituted theophyllines have been synthesized. The substituents are aromatic rings and heterocycles likely to induce an antiallergic effect or a spasmolytic activity. In vitro evaluation of the bronchospasm caused by acetylcholine or histamine shows an interesting activity for half of the compounds. Among them, the furanic IIIs and 2-chlorophenyl IIIi derivatives are, for instance, four times more active than theophylline.

  DOI：

  10.1016/0223-5234(96)88233-x
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 1,2,3,4-tetrahydro-[2]naphthoyl chloride
  参考文献：
  名称：

  The Catalytic Dehydrogenation of 2-Substituted Tetrahydronaphthalene Derivatives

  摘要：

  DOI：

  10.1021/ja01178a019

文献信息

• Synthesis and structure–activity relationships of novel arylalkyl 4-benzyl piperazine derivatives as σ site selective ligands
  作者：S Younes

  DOI：10.1016/s0223-5234(00)00113-6

  日期：2000.1

  Continuing our previous work that established that some chromones substituted by an aryl alkyl piperazino alkyl side chain are potent and selective sigma ligands and could be interesting in the treatment of psychosis, we synthesized 60 new compounds, replacing the chromone moiety by various cyclic systems. Many derivatives bind to the sigma sites in the nanomolar range and are generally selective in comparison

  继续我们先前的工作，即确定被芳基烷基哌嗪子烷基侧链取代的某些色酮是有效的选择性σ配体，在精神病治疗中可能是令人感兴趣的，我们合成了60种新化合物，用各种环状系统取代了色酮部分。许多衍生物与纳摩尔范围内的sigma位点结合，与5HT（1A）和D（2）受体相比通常具有选择性。这些系列中最有效的配体之一，是1-（2-萘甲基）-4-苄基哌嗪29，已在各种药理试验中得到了研究。尽管它在治疗精神病方面没有潜力，但我们获得的结果证实了数据，表明这些衍生物可能在炎性疾病的治疗中令人感兴趣。
• SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20150038546A1

  公开（公告）日：2015-02-05

  The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.

  本发明提供了钙感应受体调节剂（CaSR）。特别是，本发明的化合物可用于治疗、管理和/或减轻与钙感应受体（CaSR）调节相关的疾病、障碍、综合征和/或症状。本发明还提供了其药物组合物，以及用于治疗、管理和/或减轻与CaSR调节相关的疾病、障碍、综合征和/或症状的方法。本发明还涉及用于制备本发明化合物的过程。
• N,N-disubstituted arylcycloalkylamines, the salts thereof,
  申请人：Karl Thomae GmbH

  公开号：US05455273A1

  公开（公告）日：1995-10-03

  The invention relates to N,N-disubstituted arylcycloalkylamines of general formula ##STR1## wherein n, m, A, X and R.sup.1 to R.sup.7 are defined as in claim 1, the isomers, isomer mixtures and salts thereof, which have valuable properties, particularly an inhibitory effect on cholesterol biosynthesis.

  该发明涉及一般式##STR1##的N,N-二取代芳基环烷胺，其中n、m、A、X和R.sup.1至R.sup.7的定义如权利要求1中所述，其异构体、异构体混合物和盐，具有有价值的特性，特别是对胆固醇生物合成具有抑制作用。
• Aromatic amine derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05508306A1

  公开（公告）日：1996-04-16

  This invention relates to novel aromatic amine compounds having the structure: ##STR1## where each W, Z.sup.1 and Z.sup.2 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, OH, F, Cl, Br, I, NO.sub.2, CN, SO.sub.2 NHR.sup.3, NR.sup.4.sub.2, CONR.sup.3.sub.2, COR.sup.5 ; where each R.sup.1 and R.sup.2 is independently H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where each X and Y is independently CH.sub.2, NR.sup.4, S, S.dbd.O, SO.sub.2 ; where n is 0, 1 or 2; where each p and q is independently 1 or 2; where R.sup.3 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where R.sup.4 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or COR.sup.3 ; and where R.sup.5 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl, C.sub.1 -C.sub.6 straight or branched chain alkoxy or OH. In addition the invention includes using such compounds for the treatment of benign prostatic hyperplasia, lowering intraocular pressure and inhibiting cholesterol synthesis.

  这项发明涉及具有以下结构的新型芳香胺化合物：其中每个W，Z.sup.1和Z.sup.2独立地为H，C.sub.1 -C.sub.6烷基，C.sub.1 -C.sub.6烷氧基，OH，F，Cl，Br，I，NO.sub.2，CN，SO.sub.2NHR.sup.3，NR.sup.4.sub.2，CONR.sup.3.sub.2，COR.sup.5；其中每个R.sup.1和R.sup.2独立地为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中每个X和Y独立地为CH.sub.2，NR.sup.4，S，S.dbd.O，SO.sub.2；其中n为0、1或2；其中每个p和q独立地为1或2；其中R.sup.3为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中R.sup.4为H，C.sub.1 -C.sub.6直链或支链烷基或COR.sup.3；其中R.sup.5为H，C.sub.1 -C.sub.6直链或支链烷基或苯基，C.sub.1 -C.sub.6直链或支链烷氧基或OH。此外，该发明还包括使用这些化合物治疗良性前列腺增生、降低眼内压和抑制胆固醇合成。
• [EN] MEDICAMENTS<br/>[FR] MÉDICAMENTS
  申请人：MOTAC NEUROSCIENCE LTD

  公开号：WO2009056805A1

  公开（公告）日：2009-05-07

  A compound of formula (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.

  描述了一种化合物的化学式(I)：其中R1和R2如文本中定义的那样，这些化合物旨在用于治疗以多巴胺受体活性失衡为特征的医疗状况。